Acinetobacter baumannii causes difficult-to-treat infections mostly among
immunocompromised patients. Clinically relevant A. baumannii lineages and their …

Objectives Novel therapeutics are urgently required for the treatment of carbapenem-
resistant Acinetobacter baumannii (CRAB) causing critical infections with high mortality …

Carbapenem resistant Acinetobacter baumannii has emerged as one of the most difficult to
treat nosocomial bacterial infections in recent years. It was one of the major causes of …

Multidrug-resistant A. baumannii (MDRAB) VAP has high morbidity and mortality, and the
rates are constantly increasing globally. Mono-and polybacterial MDRAB VAP might differ …

The inappropriate and inconsistent use of antibiotics in combating multidrug-resistant
bacteria exacerbates their drug resistance through a few distinct pathways. Firstly, these …

Infections caused by carbapenem-resistant Acinetobacter baumannii (CRAB) present
significant healthcare challenges due to limited treatment options. Bacteriophage (phage) …

We have already entered the post‐antibiotic era as the outbreaks of numerous multidrug‐
resistant strains in the community as well as hospital‐acquired infections are ringing alarm …

Background Antibiotic resistance is a major threat to public health worldwide. The
relationship between the intensity of antibiotic use and resistance might not be linear …

In recent years, the treatment of Acinetobacter baumannii infections has become a pressing
clinical challenge due to its increasing incidence and its serious pathogenic risk. The …

Amikacin and polymyxins as monotherapies are ineffective against multidrug-resistant
Acinetobacter baumannii at the clinical dose. When polymyxins, aminoglycosides, and …